Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

about

Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.Nonclinical assessment of tumor growth enhancement potential by B2A-coated ceramic granules used in arthodesis.

P2860

Q33785128-54B02D6A-2BA5-4E0B-8B37-56E81EDF430D Q39191962-4624D0BF-E8E9-4C68-85BD-4B736BECC865

P2860

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

Item

http://www.wikidata.org/entity/Q39332214

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Nonclinical assessment of carc ...... -inhibiting therapeutic agent.

@en

Nonclinical assessment of carc ...... -inhibiting therapeutic agent.

@nl

type

Item

label

Nonclinical assessment of carc ...... -inhibiting therapeutic agent.

@en

Nonclinical assessment of carc ...... -inhibiting therapeutic agent.

@nl

prefLabel

Nonclinical assessment of carc ...... -inhibiting therapeutic agent.

@en

Nonclinical assessment of carc ...... -inhibiting therapeutic agent.

@nl

P1476

Nonclinical assessment of carc ...... -inhibiting therapeutic agent.

@en

P2093

Atsushi Sanbuissho

http://www.w3.org/2001/XMLSchema#string

James J Starling

http://www.w3.org/2001/XMLSchema#string

Joseph A Jakubowski

http://www.w3.org/2001/XMLSchema#string

Lorrene A Buckley

http://www.w3.org/2001/XMLSchema#string

Mary Pat Knadler

http://www.w3.org/2001/XMLSchema#string

Philip W Iversen

http://www.w3.org/2001/XMLSchema#string

P2860

P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B

Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells

Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.

Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.

Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion.

Weighing benefits and risks--the FDA's review of prasugrel.

Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy.

Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells.

Cancer among epileptic patients exposed to anticonvulsant drugs.

Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: the dalcetrapib experience.

P304

317-325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1091581812445073

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22692976

http://www.w3.org/2001/XMLSchema#string

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

about

P2860

P2860

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698